Posts by Sandra Ansanay-Alex
European Academy of Neurology – Call for Abstract
Apply before 14 January 2027 for the European Academy of Neurology and get a chance to present your work at the event (12 – 15 June 2027 – Göteborg – Sweden) The EAN has long been known as Europe’s Home of Neurology, and this year the EAN Congress 2027 brings together the global neurology community…
Read MoreSwiss Italian Startup Award
The Swiss Italian Startup Award is taking place on 24 November 2026 at Campus Biotech Geneva The Swiss Italian Startup Award returns to Campus Biotech for its 3rd edition, once again bringing together leading Italian entrepreneurs and investors in Geneva. Organised by the Italian Chamber of Commerce for Switzerland in partnership with several ecosystem partners, the event celebrates innovation, entrepreneurship and cross-border cooperation, strengthening…
Read MoreBewe Lab Gets Support from Lichtsteiner Foundation
Changing eating and drinking habits doesn’t have to start with restriction. Bewe Lab, a spinoff of the University of Fribourg (UNIFR) based in Biopôle Epalinges, is taking a different approach to a complex and often overlooked challenge: understanding and managing compulsive behaviours. The start-up just secured support from Lichtsteiner foundation. Measuring cravings through play Bewe…
Read MoreSwiss Biotech Association appoints Nicolas Durand as CEO and Odile Rundquist as Chief Strategy & Growth Officer
The Swiss Biotech Association has appointed Nicolas Durand as CEO, effective 1 January 2027, and Odile Rundquist as Chief Strategy & Growth Officer, as of 1 December 2026. Nicolas Durand will assume overall executive responsibility for the association, while Odile Rundquist will focus on strategic development, partnerships, and access to capital. The association’s priorities remain unchanged: supporting its members and strengthening…
Read MoreExcellGene celebrates 25 years of biotechnology innovation
Based in Monthey (VS) since 2003, ExcellGene last week celebrated 25 years of biotechnology innovation also marking the leadership transition from Maria J. Wurm, former Chief Executive Officer, to its new CEO, Luca Valeggia. Founded in 2001, ExcellGene was the first biotechnology company in Valais, a spark that gave rise to the entire local biotech…
Read MoreHUG to Lead a Major Trial Testing Cell Therapy for Advanced Heart Failure
Geneva University Hospitals (HUG) has received over CHF 1 million from the Swiss National Science Foundation to take part in RenuHEART, an international phase III trial that uses patients’ own bone marrow cells to treat heart failure. Heart failure affects more than 26 million people worldwide, including over 100,000 in Switzerland. Patients whose disease is…
Read MoreTwice as many Swiss now ask AI about their symptoms
The 2026 CSS Health Study shows chatbots are fast becoming part of how people in Switzerland manage their health, from checking symptoms to coping with loneliness. Not feeling well? More and more people in Switzerland now ask a chatbot before they call a doctor. According to the 2026 CSS Health Study, 42% of respondents have…
Read MoreIbex Therapeutics Secures CHF 640,000 in Grant Funding from Innosuisse
The Valais-based start-up is accelerating the development of its lead candidate in partnership with the Geneva University Hospitals (HUG) and the University of Applied Sciences and Arts of Western Switzerland (HES-SO Valais-Wallis). This scientific innovation project aims to validate the therapeutic efficacy and synergy of active ingredients derived mainly from Swiss alpine plants to treat…
Read MoreApolarion receives CHF 150,000 from Venture Kick
The EPFL spin-off Apolarion has obtained CHF 150,000 from Venture Kick to advance a chemical-free seed treatment technology powered by plasma. Using only air and electricity, the cleantech startup aims to protect crops from harmful pathogens while reducing the environmental impact of agriculture. Protecting seeds from disease is essential to ensuring healthy crops and reliable…
Read MoreLonza Acquires Acquires Five CDMO Manufacturing Sites in the US
Lonza, the largest Swiss Health Valley🇨🇭 company, signs an agreement with Merck KGaA to acquire five CDMO manufacturing sites and approximately 1,100 highly skilled employees in the US, more than doubling its US footprint to nine CDMO sites with a US workforce of more than 6,000 employees. Lonza will acquire the assets and associated businesses at…
Read More